ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook

ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance

May 9, 2019 8:30 AM EDT

BAUDETTE, Minn., May 9, 2019 /PRNewswire/ --

For the first quarter 2019:

Net revenues of $52.9 million, an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share of $0.04 Record adjusted non-GAAP EBITDA of $22.3 million Adjusted non-GAAP diluted earnings per share of $1.30

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported its financial results for the three months ended March 31, 2019 and reaffirmed its 2019 financial guidance. The Company will host its earnings conference call this morning, May 9,... More